Please provide your email address to receive an email when new articles are posted on . Danish registry data show 31% of people with obesity and a first MI met SELECT trial criteria and are eligible ...
VENICE, Italy — Four-year data from the SELECT cardiovascular outcomes trial show that the anti-obesity drug semaglutide (Wegovy) leads to clinically significant and durable weight loss, as well as ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Finerenone reduced the incidence of the primary composite endpoint of CV death, nonfatal MI, nonfatal stroke or hospitalization for heart failure by 13%. The prescribing information for Kerendia ® ...
Pregnant women with COVID-19 are at increased risk of severe disease, ICU stays, and adverse pregnancy and child-health outcomes, with the greatest risks in the unvaccinated population, a new state-of ...
Data expected this summer evaluating a potential cardiovascular risk reduction from Novo Nordisk's (NVO) obesity drug Wegovy (semaglutide) could benefit both the Danish pharma and Eli Lilly (NYSE:LLY) ...
Compared with heterosexual females, those who are bisexual have less favorable scores on standardized measures of CV health, new data show. The same study, however, found that gay males tend to have ...
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J. & CHICAGO--(BUSINESS WIRE)--Kardiga n, a heart health company modernizing cardiovascular (CV) drug development, announced today that it has acquired ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results